CGRP antagonists 5 years on – what has been learned?TANDEM trial supports efficacy of dual therapy with ubrogepant and atogepant Do CGRP mAbs act centrally as well as peripherally?European registries show comparable CGRP mAb efficacy to clinical trials Galcanezumab superior to amitriptyline and topiramate Aquipta (atogepant) receives EU approval for migraine prevention PROGRESS results for atogepant in chronic migraine published CGRP mAbs show efficacy in vestibular migraine

CGRP in cluster headache

22 January 2020 | Videos

In the third in his series of videos about the future of CGRP therapies, Peter Goadsby describes the research that led to the approval of galcanezumab for the treatment of episodic cluster headache and looks forward to better understanding of how treatment can be optimised for patients most likely to benefit.

Educational Partners and Supporters (others pending)

Amgen

Biohaven

Lilly

Novartis

This program is funded in part via an independent educational grant from AbbVie

Editorial PolicyCGRP Forum is an expert resource for clinicians and healthcare professionals working with migraine patients. All patients should discuss their medication with their healthcare professional. Unless otherwise indicated, opinions expressed in the CGRP Education and Research Forum are those of the contributors. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the CGRP Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

© 2023 | Privacy Policy | Editorial Policy | Governance | Disclaimer Statement | Partnership & Outreach |